Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lifecare AS ( (DE:LFC0) ) just unveiled an update.
Lifecare ASA has announced the completion of the exercise period for its Series 1 warrants linked to the January 2026 rights issue, with holders exercising 107,059,776 out of 129,000,033 warrants at an exercise price of NOK 0.3342 per share. The resulting new shares are expected to be paid, registered with the Norwegian Register of Business Enterprises, and delivered to investors’ VPS accounts in late March, after which they will be tradable and listed on Euronext Oslo Børs under the ticker LIFE, strengthening the company’s equity base and liquidity while remaining subject to standard regulatory and settlement conditions.
More about Lifecare AS
Lifecare ASA is a medical sensor company specialising in technology for sensing and monitoring various body analytes, with a core focus on next‑generation continuous glucose monitoring systems. The company’s osmotic pressure–based sensor platform is designed to detect and track a wide range of analytes and molecules in humans and pets, targeting advanced diagnostic and monitoring applications.
Average Trading Volume: 3,951,568
Current Market Cap: NOK114.6M
Find detailed analytics on LFC0 stock on TipRanks’ Stock Analysis page.